George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Regulatory News (SAR)

Share Price Information for Sareum (SAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 10.75
Bid: 10.50
Ask: 11.00
Change: 0.00 (0.00%)
Spread: 0.50 (4.762%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 10.75
SAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Research Update - SDC-1802 anti-cancer poster

30 Oct 2019 07:00

RNS Number : 5350R
Sareum Holdings PLC
30 October 2019
 

(AIM: SAR)30 October 2019

SAREUM HOLDINGS PLC

("Sareum" or the "Company")

Sareum presents data highlighting the anti-tumour activity of TYK2/JAK1 Inhibitor SDC-1802 in multiple cancer disease models via a novel immunotherapeutic mechanism of action

Poster presented at AACR-NCI-EORTC cancer conference

Sareum Holdings plc, the specialist small molecule drug development business, announces that its CEO, Dr Tim Mitchell, presented data yesterday demonstrating how SDC-1802 (formerly known as SAR-20351), a novel selective TYK2/JAK1 inhibitor discovered by Sareum, significantly reduces tumour growth in disease models of cancers of the pancreas, colon, skin and kidney, plus B-cell lymphoma. The studies showed that SDC-1802 induces this anti-cancer activity through a novel immunotherapeutic mechanism of action that stimulates the local immune system to attack cancer cells. 

These positive results were seen when SDC-1802/SAR-20351 was dosed orally, both as a monotherapy and in combination with standard-of-care therapies. These data provide support for TYK2/JAK1 inhibition as a potentially powerful new immunotherapy approach and for the further development of SDC-1802 as a novel cancer therapeutic.

The data were presented in a poster at the American Association for Cancer Research (AACR) National Cancer Institute (NCI) European Organisation for Research and Treatment of Cancer (EORTC) International Conference (26-30 October 2019 in Boston, USA). The poster entitled "Immunotherapeutic effects of the TYK2 inhibitor SAR-20351 in syngeneic tumour models" (Abstract C086) has been published on the Company's website at http://www.sareum.com/news/patents-and-publications.

Sareum's CEO, Dr Tim Mitchell, commented: "We were pleased to present these data highlighting the anti-tumour effects of our oral TYK2/JAK1 inhibitor SDC-1802 and its immunotherapeutic mechanism yesterday at AACR-NCI-EORTC. The conference is an important international cancer congress showcasing innovative research from academic and pharmaceutical organisations from around the world. There was a good level of interest directed at novel immunotherapy mechanisms such as TYK2/JAK1 inhibition and we look forward to further discussions with interested parties."

For further information, please contact: 

Sareum Holdings plc

 

Tim Mitchell

01223 497 700

Strand Hanson Limited (Nominated Adviser)

James Dance / Richard Tulloch

020 7409 3494

Hybridan LLP (Nominated Broker)

 

Claire Noyce / John Beresford-Peirse

020 3764 2341

Citigate Dewe Rogerson (Media enquiries)

 

Shabnam Bashir/ Mark Swallow/ David Dible

020 7638 9571

Notes for editors:

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune disease. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases (SDC-1801) and cancers (SDC-1802). The Company is targeting first human clinical trials in each indication in 2020.

Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Preliminary data suggest SRA737 may have broad application in combination with other oncology and immune-oncology drugs in genetically defined patients. SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to Sierra Oncology, in a $328.5m plus royalties licence deal, with Sareum eligible to receive 27.5% of all payments to CPF under the agreement.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.co.uk.

Cancer Immunotherapy, also known as immuno-oncology, is a form of cancer treatment that uses the power of the body's own immune system to prevent, control, and eliminate cancer. Cancer Immunotherapy can:

• Educate the immune system to recognise and attack specific cancer cells;

• Boost immune cells to help them eliminate cancer; and

• Provide the body with additional components to enhance the immune response.

Unleashing the power of the immune system is considered to be a smart way to fight cancer because:

• The immune system is precise, so it is possible for it to target cancer cells exclusively while sparing healthy cells;

• The immune system can adapt continuously and dynamically, just like cancer does, so if a tumour manages to escape detection, the immune system can re-evaluate and launch a new attack; and

• The immune system's "memory" allows it to remember what cancer cells look like, so it can target and eliminate the cancer if it returns.

(Source: The Cancer Research Institute, www.cancerresearch.org)

 

- Ends -

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RESLLFLDIRLAFIA
Date   Source Headline
28th Mar 20247:02 amRNSWRAP Retail Offer
28th Mar 20247:01 amRNSEquity Fundraise
28th Mar 20247:00 amRNSSareum Half-Year Report
15th Mar 20247:00 amRNSNew Patent Allowance
12th Mar 20241:30 pmRNSNotice of Interim Results and Trading Update
15th Feb 20247:00 amRNSUpdate on SDC-1801 Clinical Trial Progress
2nd Jan 20247:00 amRNSDevelopment and commercialisation licence SRA737
14th Dec 20233:35 pmRNSResults of AGM
14th Dec 20237:00 amRNSAnnual General Meeting Statement
23rd Nov 20237:00 amRNSDrawdown of Equity Prepayment Facility
21st Nov 20237:00 amRNSNotice of AGM, Annual Report and Accounts
9th Nov 20237:00 amRNSInitiation of food effects study for SDC-1801
8th Nov 20233:03 pmRNSDirector Dealings
3rd Nov 20237:05 amRNSSareum enhances SDC-1801 patent protection
2nd Nov 20232:48 pmRNSExercise of Share Options and Director Dealings
9th Oct 20237:00 amRNSFinal Results for the Year Ended 30 June 2023
3rd Oct 20237:00 amRNSNotice of Results and Investor Presentation
6th Sep 20237:00 amRNSDirector's Dealing
5th Sep 20237:00 amRNSDirector Dealing
4th Sep 20237:00 amRNSDosing of first subjects in MAD Phase 1a trial
16th Aug 20237:00 amRNSUpdate on financial and operational progress
3rd Aug 20237:00 amRNSEquity Prepayment Facility of up to £5 million
26th Jun 20237:00 amRNSSareum Announces Two New Granted Patents
6th Jun 20237:00 amRNSDosing commences in Phase 1a trial of SDC-801
18th May 20237:00 amRNSPhase 1a clinical trial for SDC-1801
5th May 20239:20 amRNSApproval to initiate Phase 1 clinical trial
22nd Mar 20237:00 amRNSHalf-Year Report
15th Mar 20237:01 amRNSUpdate on SDC-1801
15th Mar 20237:00 amRNSNotice of Half-Year Results
6th Mar 20237:00 amRNSUpdate on SRA737
29th Dec 20223:14 pmRNSDirector/PDMR Shareholding
16th Dec 20223:29 pmRNSResults of AGM
16th Dec 20227:00 amRNSAGM Statement
24th Nov 20227:00 amRNSNotice of AGM, Annual Report and Accounts
21st Nov 20227:00 amRNSSareum notes publication of SRA737 clinical data
9th Nov 20224:41 pmRNSSecond Price Monitoring Extn
9th Nov 20224:35 pmRNSPrice Monitoring Extension
9th Nov 20222:05 pmRNSSecond Price Monitoring Extn
9th Nov 20222:00 pmRNSPrice Monitoring Extension
9th Nov 202211:05 amRNSSecond Price Monitoring Extn
9th Nov 202211:00 amRNSPrice Monitoring Extension
9th Nov 20229:05 amRNSSecond Price Monitoring Extn
9th Nov 20229:00 amRNSPrice Monitoring Extension
8th Nov 20225:23 pmRNSUpdate on SDC-1801 CTA Application
24th Oct 20227:00 amRNSFinal Results for the Year Ended 30 June 2022
12th Oct 20227:00 amRNSUpdate on SRA737
30th Sep 20224:41 pmRNSSecond Price Monitoring Extn
30th Sep 20224:36 pmRNSPrice Monitoring Extension
12th Sep 20227:00 amRNSSareum notes FDA approval of first TYK2 Inhibitor
28th Jul 20227:00 amRNSCTA application to MHRA and Corporate Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.